NEWS

Feds Taking “Stock” of Curaleaf

 

U.S.-based medical and cannabis operator, Curaleaf, finds itself in more problems since the Food and Drug Administration (FDA) publicized that the firm was making unsubstantial health claims about its products. While the CuraLeaf did remove all claims after being warned by the federal agency, it has now been accused of violating federal securities law. Simply put, Curaleaf’s health claims is reasoned as a securities violation because the spreading of falsified material is trusted as a scheme to increase the firm’s securities market prices.

RECENTLY FEATURED IN NEWS

May News

Does THC Cause Reefer Madness?  It might sound crazy, but a review of existing research found that a single dose of THC in cannabis —

Read More »

April News

Finally Some Good News for Vaping After months of pressure from the scientific community, the American Heart Association’s academic journal retracted a widely circulated vaping

Read More »
Cannabis on Deck

March News

In a move that raised many eyebrows, Major League Baseball (MLB) and the players union announced they had reached an agreement to remove cannabis from

Read More »

Will CBD Be Safer Soon?

President Trump has requested $5 million dollars to regulate the CBD industry in its new FY2021 budget. Specifically, the request would “allow the Food and

Read More »

For more information regarding Coronavirus (COVID-19)

please sign up for our newsletter


By submitting this form, you are consenting to receive marketing emails from: HQ Magazine, 9901 Acoma Rd SE, Albuquerque, NM, 87123. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact